Summary

Anthem Biosciences Limited, a CRDMO, announced its unaudited results for the third quarter and period ended December 31, 2025. The company reported a revenue from operations of ¥4,232 Mn for Q3FY26 and ¥15,134 Mn for 9MFY26. The EBITDA for Q3FY26 was ¥1,907 Mn and for 9MFY26 was ¥6,712 Mn. The PAT for Q3FY26 was £928 Mn and for 9MFY26 was ¥74,020 Mn. The company's CRDMO specialty ingredients contributed ¥4,719 Mn to the total revenue for 9MFY26.

Key Highlights

1. 1

   Revenue from Operations for Q3FY26: ¥4,232 Mn

2. 2

   Revenue from Operations for 9MFY26: ¥15,134 Mn

3. 3

   EBITDA for Q3FY26: ¥1,907 Mn

4. 4

   EBITDA for 9MFY26: ¥6,712 Mn

5. 5

   PAT for Q3FY26: £928 Mn

6. 6

   PAT for 9MFY26: ¥74,020 Mn

7. 7

   CRDMO Specialty Ingredients revenue for 9MFY26: ¥4,719 Mn